Litcius/Paper detail

Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS

Dongfang Li, Yuying Kou, Yuan Gao, Shanshan Liu, Panpan Yang, Tomoka Hasegawa, Rongjian Su, Jie Guo, Minqi Li

2021Aging32 citationsDOIOpen Access PDF

Abstract

. Further experiments proved that oxaliplatin induced parthanatos in OSCC cells, characterized by depolarization of the mitochondrial membrane potential, up-regulation of PARP1, AIF and MIF in the nucleus, as well as the nuclear translocation of AIF. Meanwhile, PARP1 inhibitor rucaparib and siRNA against PARP1 attenuated oxaliplatin-induced parthanatos in OSCC cells. In addition, we found that oxaliplatin caused oxidative stress in OSCC cells, and antioxidant NAC not only relieved oxaliplatin-induced overproduction of reactive oxygen species (ROS) but also reversed parthanatos caused by oxaliplatin. In conclusion, our results indicate that oxaliplatin inhibits OSCC by activating PARP1-mediated parthanatos through increasing the production of ROS.

Topics & Concepts

Basal cellCancer researchPARP1OxaliplatinMedicineBiologyInternal medicineCancerPoly ADP ribose polymeraseColorectal cancerGeneticsGenePolymerasePARP inhibition in cancer therapyHead and Neck Cancer StudiesCell death mechanisms and regulation
Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS | Litcius